MARKET

SABS

SABS

SAB BIOTHERAPEUTICS INC
NASDAQ
3.999
+0.379
+10.46%
Opening 15:36 01/07 EST
OPEN
3.860
PREV CLOSE
3.620
HIGH
4.000
LOW
3.650
VOLUME
406.44K
TURNOVER
--
52 WEEK HIGH
6.60
52 WEEK LOW
1.000
MARKET CAP
190.37M
P/E (TTM)
-1.4254
1D
5D
1M
3M
1Y
5Y
1D
UBS Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $7
Benzinga · 10m ago
SAB Biotherapeutics Appoints New Independent Board Chair, Directors
TipRanks · 6h ago
SAB Biotherapeutics initiated with a Buy at UBS
TipRanks · 7h ago
Aligos Therapeutics initiated with a Buy at UBS
TipRanks · 7h ago
SAB Biotherapeutics appoints David Zaccardelli as board chair
TipRanks · 7h ago
SAB Biotherapeutics Appoints David Zaccardelli As Board Chair.
Benzinga · 7h ago
*SAB Biotherapeutics Says Rita Jain Joins Board as an Independent Director >SABS
Dow Jones · 7h ago
SAB Biotherapeutics Names David Zaccardelli as Board Chair and Rita Jain as Director
Reuters · 7h ago
More
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Webull offers SAB Biotherapeutics Inc stock information, including NASDAQ: SABS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SABS stock methods without spending real money on the virtual paper trading platform.